Tekmira Cleared to Begin Phase I Testing of Cancer Drug

The drug is comprised of an siRNA designed to silence polo-like kinase 1, a cell cycle protein implicated in tumor cell proliferation, and a novel lipid delivery vehicle, the company said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.